Financial Tearsheet

Company Overview

ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare.

ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care.

ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.

Recent Financial News

IR Contacts

Gregory FCA

Joe Hassett
484-686-6600
joeh@gregoryfca.com
https://www.gregoryfca.com/

Stock Performance

Today's Open 0.8648
Volume 142,523
Day Range 0.8300 - 0.9000
52 Week Range 0.5990 - 2.2500
Bid/Ask 0.8456 / 0.8500
Bid/Ask Size 200 X 1,700
Previous Close 0.8353
Market Cap 21.35 million
Shares Outstanding 25.1 million
Dividend/Yield 0.0000 / 0.0000%
EPS (TTM) -1.830400
P/E Ratio (TTM) N/A

Recent XBRL Filings

Filing Date Form Type Description View
Nov 16, 2020 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Aug 14, 2020 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
May 14, 2020 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Mar 26, 2020 10-K Annual report htmlhtml   pdfpdf   xbrlxbrl  
Nov 13, 2019 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  

Management Team

Francois Michelon, Chief Executive Officer and Chairman

Michael Thornton, Chief Technology Officer

David Wells, Chief Financial Officer

Amy Sitzler, Vice President of Engineering and Programs

Steve Freeman, Human Resources Leader

Renaud Maloberti, Chief Commercial Officer

Board of Directors

Francois Michelon, Chairman of the Board

Louis Basenese, Director

Anthony DiGiandomenico, Director

Michael Harsh, Director

Alexander Tokman, Director